Floatz logo

Everolimus

Mesothelioma, Malignant

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanySmall moleculePhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

18 Active assets in the Mesothelioma, Malignant cohort.

Asset / SponsorPhaseRating
Tulmimetostat
Novartis Pharmaceuticals
Phase 1/2CC
a2b543
A2 Biotherapeutics Inc.
Phase 1/2CC
Ipilimumab
TCR2 Therapeutics
Phase 1/2CC
Fludarabine
M.D. Anderson Cancer Center
Phase 1/2CC
Gavo-Cel
TCR2 Therapeutics
Phase 1/2CC

View all 18 →

Same molecule, other indications

Everolimus is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
76 / 100
View asset →
hormone receptor-positive breast cancerDormant
BBB
Indicative ·
75 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →